Get started
Author

Wendy Painter

Observed names: W. P. Painter, W. Painter, Wendy P Painter, Wendy P. Painter
ORCID: 0000-0001-6710-1277
Observed ORCID: 0000-0001-6710-1277
OpenAlex ID: A5078260740
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
2021 · William A. Fischer, Joseph J. Eron, et al. · Science Translational Medicine · 540
Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2
2021 · Wendy P. Painter, Wayne Holman, et al. · Antimicrobial Agents and Chemotherapy · 396
First Pharmacokinetic and Safety Study in Humans of the Novel Lipid Antiviral Conjugate CMX001, a Broad-Spectrum Oral Drug Active against Double-Stranded DNA Viruses
2012 · Wendy Painter, Alice Robertson, et al. · Antimicrobial Agents and Chemotherapy · 179
Safety and Efficacy of CMX001 as Salvage Therapy for Severe Adenovirus Infections in Immunocompromised Patients
2011 · Diana F. Florescu, Steven A. Pergam, et al. · Transplantation and Cellular Therapy · 179
PDF
Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19
2021 · George R Painter, Michael G Natchus, et al. · Current Opinion in Virology · 172
Development of CMX001 for the Treatment of Poxvirus Infections
2010 · Randall Lanier, Lawrence Trost, et al. · Viruses · 168
PDF
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
2021 · Saye H Khoo, Richard Fitzgerald, et al. · Journal of Antimicrobial Chemotherapy · 122
PDF
Progressive Vaccinia: Case Description and Laboratory-Guided Therapy With Vaccinia Immune Globulin, ST-246, and CMX001
2012 · E. R. Lederman, W. Davidson, et al. · The Journal of Infectious Diseases · 122
Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001
2010 · Kris Paolino, Jane Sande, et al. · Journal of Clinical Virology · 89
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
2022 · Saye H Khoo, Richard FitzGerald, et al. · The Lancet Infectious Diseases · 82
PDF
Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2
2021 · Wendy Holman, Wayne Holman, et al. · Trials · 53
PDF
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
2022 · Richard FitzGerald, Laura Dickinson, et al. · Clinical Infectious Diseases · 24
PDF
The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection
2022 · Gregory R. Bluemling, Shuli Mao, et al. · Antiviral Research · 18
PDF
Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates
2021 · Katie R Mollan, Joseph J Eron, et al. · Clinical Infectious Diseases · 14
PDF
Reduction in infectious sars-cov-2 in treatment study of covid-19 with molnupiravir
2021 · Wendy Painter, Timothy P. Sheahan, et al. · Topics in antiviral medicine · 10
Population pharmacokinetics of molnupiravir in adults with COVID ‐19: Lack of clinically important exposure variation across individuals
2023 · Sébastien Bihorel, Youfang Cao, et al. · CPT Pharmacometrics & Systems Pharmacology · 9
PDF
CMX001 for Prevention and Control of CMV Infection in CMV-Seropositive Allogeneic Stem-Cell Transplant Recipients: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial of Safety, Tolerability and Antiviral Activity
2012 · F.M. Marty, D. Winston, et al. · Transplantation and Cellular Therapy · 8
Results of a phase Ib study of Q-122 treatment of vasomotor symptoms in breast cancer patients.
2015 · Wendy Painter, April L. Speed, et al. · Journal of Clinical Oncology · 5
Experience With CMX001, a Novel Antiviral Drug, for Cytomegalovirus infections in Stem Cell Transplant Patients
2011 · G. Papanicolau, J. Kurtzberg, et al. · Transplantation and Cellular Therapy · 5
Cmx001 as Therapy for Severe Adenovirus Infections in Immunocompromised Pediatric Patients: Single Experience in 5 Patients
2012 · M.S. Grimley, R.A. Marsh, et al. · Transplantation and Cellular Therapy · 3
PDF
The Challenges of Developing an Antiviral Agent for the Treatment of Smallpox Using the Animal Efficacy Rule
2006 · George Painter, Mark Buller, et al. · Future Virology · 3
CMX001 (Hexadecyloxypropyl Cidofovir) Antiviral Activity against Adenovirus in Patients Correlates with Drug Levels and Viral Sensitivity
2011 · E.R. Lanier, W. Painter, et al. · Antiviral Research · 2
Comparison of Molnupiravir Exposure‐Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID ‐19
2025 · Akshita Chawla, Ruthie Birger, et al. · Clinical and Translational Science · 1
The Antiviral Mechanism of Action of Molnupiravir in Humans with COVID-19
2023 · Timothy P. Sheahan, Laura J. Stevens, et al. · medRxiv · 1
PDF
Accelerated First-in-Human Clinical Trial of EIDD-2801/MK-4482 (molnupiravir), a Ribonucleoside Analogue with Potent Antiviral Activity Against SARS-CoV-2
2021 · Oren Cohen, Wendy Holman, et al. · Research Square · 1
PDF
Works count: 30
Citation count: 2,206
H-index: 14
I10-index: 15
Year
Topic
Type